Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: May 2008
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Salix Pharmaceuticals, Inc. et al. v. Novel Laboratories, Inc.3:08-cv-02311; filed May 14, 2008 in the District Court of New Jersey Infringement of…
-
By Kevin E. Noonan — An important consequence of the biotechnology revolution has been an increased understanding of the molecular biology of cancer. Tyrosine kinases, including the eponymous src oncogene, provide important targets, comprising a family of plasma membrane proteins that in certain incarnations act as growth factor receptors. Until now, therapeutic agents…
-
May 28, 2008 – Advanced Patent Licensing 2008: What You Need to Know Before Licensing Your Patent (Practising Law Institute) – New York, NY May 28-30, 2008 – PharmaBiotech IP Summit (Worldwide Business Research) – Philadelphia, PA June 11, 2008 – Advanced Patent Licensing 2008: What You Need to Know Before Licensing Your Patent (Practising…
-
American Conference Institute (ACI) will be holding its 10th Annual Forum on Biotech Patents on September 15-16 in Boston, MA. The conference will allow attendees to: • Establish essential strategies to prepare their companies or clients in light of frenzied upheaval in the patent world;• Analyze the profound and potentially earth shattering ramifications of recent…
-
American Conference Institute (ACI) will be holding the next session of its FDA Boot Camp conference on September 22-23 in Boston, MA. The conference will allow attendees to: • Master the basics of the application and approval processes for drugs, biologics, and devices;• Comprehend the structure of the FDA and the roles of the CDER,…
-
By Kevin E. Noonan — On Tuesday, U.S. Patent Commissioner John Doll (at right) touted several initiatives being pursued in the U.S. Patent and Trademark Office to reduce the backlog of pending cases (see "Lunch with Commissioner Doll"). He also said he (and the rest of PTO management) welcomed whatever creative ideas that…
-
By Donald Zuhn — Earlier this month, the monthly healthcare marketing publication Medical Marketing & Media (MM&M) announced the release of The Pharma Report 2008, MM&M’s list of the top twenty pharmaceutical companies (as determined by U.S drug sales in 2007). According to MM&M’s report, the top twenty pharma companies for 2007 were:…
-
By Kevin E. Noonan — One of the frustrations of those opposed to actions taken by the Administration over the past eight years has been the lack of Congressional oversight, in view of the congruency of the party in power of the legislative and executive branches. Although in theory this left the judicial…
-
By Donald Zuhn — Earlier this week, we reported on two recently filed patent cases: the first by StemCells, Inc. against Neuralstem, Inc., asserting infringement of U.S. Patent Nos. 7,115,418 and 7,361,505, and the second being filed by Neuralstem, seeking a declaratory judgment of noninfringement, unenforceability, and invalidity of the ‘505 patent. The…
-
By Kevin E. Noonan — John Doll, Commissioner for Patents of the U.S. Patent and Trademark Office, gave a luncheon seminar today concerning the state of the USPTO, hosted by the Boston office of Kirkpatrick & Lockhart Preston Gates Ellis LLP. As we’ve said before, Commissioner Doll (at right) is the happy face…
Patent Docs 